Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Breast cancer; Drug development; Immunoediting

Detalles Bibliográficos
Autores: Corti, Chiara, Cortés Castan, Javier, Mittendorf, Elizabeth, Schmid, Peter, Rugo, Hope, Tarantino, Paolo
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/7875
Acceso en línea:https://hdl.handle.net/11351/7875
Access Level:acceso abierto
Palabra clave:Mama - Càncer - Tractament
Immunoteràpia
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
id ES_74936c9e2f1093c23a42c0d41b98fa22
oai_identifier_str oai:scientiasalut.gencat.cat:11351/7875
network_acronym_str ES
network_name_str España
repository_id_str
spelling Immunotherapy for early triple negative breast cancer: research agenda for the next decadeCorti, ChiaraCortés Castan, JavierMittendorf, ElizabethSchmid, PeterRugo, HopeTarantino, PaoloMama - Càncer - TractamentImmunoteràpiaDISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast NeoplasmsOther subheadings::Other subheadings::Other subheadings::/drug therapyENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativosOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaBreast cancer; Drug development; ImmunoeditingCàncer de mama; Desenvolupament de medicaments; ImmunoedicióCáncer de mama; Desarrollo de fármacos; InmunoediciónFor decades, the systemic treatment of localized triple negative breast cancer (TNBC) has exclusively relied on chemotherapy. Recent advancements, however, are rapidly reshaping the treatment algorithms for this disease. The addition of pembrolizumab to neoadjuvant chemotherapy has indeed shown to significantly improve event-free survival for stage II–III TNBC, leading to its establishment as new standard of care in this setting. This landmark advancement has however raised several important scientific questions. Indeed, we desperately need strategies to identify upfront patients deriving benefit from the addition of immunotherapy. Moreover, the best integration of pembrolizumab with further recent advancements (capecitabine, olaparib) is yet to be defined. Lastly, extensive efforts are needed to minimize the impact on patients of immune-related adverse events and financial toxicity. The next decade of clinical research will be key to overcome these challenges, and ultimately learn how to optimally integrate immunotherapy in the treatment landscape of TNBC.Supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship.Nature ResearchInstitut Català de la Salut[Tarantino P] Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. [Corti C] Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. [Schmid P] Barts Cancer Institute, Queen Mary University of London, London, UK. [Cortes J] Oncology Department, International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Breast Cancer Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. [Mittendorf EA] Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, USA. Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA. [Rugo H] University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center Precision Medicine Cancer Building, San Francisco, USAVall d'Hebron Barcelona Hospital Campus202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/7875Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésNPJ Breast Cancer;8https://doi.org/10.1038/s41523-022-00386-1Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/78752026-06-12T09:38:37Z
dc.title.none.fl_str_mv Immunotherapy for early triple negative breast cancer: research agenda for the next decade
title Immunotherapy for early triple negative breast cancer: research agenda for the next decade
spellingShingle Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Corti, Chiara
Mama - Càncer - Tractament
Immunoteràpia
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
title_short Immunotherapy for early triple negative breast cancer: research agenda for the next decade
title_full Immunotherapy for early triple negative breast cancer: research agenda for the next decade
title_fullStr Immunotherapy for early triple negative breast cancer: research agenda for the next decade
title_full_unstemmed Immunotherapy for early triple negative breast cancer: research agenda for the next decade
title_sort Immunotherapy for early triple negative breast cancer: research agenda for the next decade
dc.creator.none.fl_str_mv Corti, Chiara
Cortés Castan, Javier
Mittendorf, Elizabeth
Schmid, Peter
Rugo, Hope
Tarantino, Paolo
author Corti, Chiara
author_facet Corti, Chiara
Cortés Castan, Javier
Mittendorf, Elizabeth
Schmid, Peter
Rugo, Hope
Tarantino, Paolo
author_role author
author2 Cortés Castan, Javier
Mittendorf, Elizabeth
Schmid, Peter
Rugo, Hope
Tarantino, Paolo
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Tarantino P] Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. [Corti C] Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. [Schmid P] Barts Cancer Institute, Queen Mary University of London, London, UK. [Cortes J] Oncology Department, International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Breast Cancer Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. [Mittendorf EA] Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, USA. Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA. [Rugo H] University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center Precision Medicine Cancer Building, San Francisco, USA
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Mama - Càncer - Tractament
Immunoteràpia
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
topic Mama - Càncer - Tractament
Immunoteràpia
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
description Breast cancer; Drug development; Immunoediting
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/7875
url https://hdl.handle.net/11351/7875
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv NPJ Breast Cancer;8
https://doi.org/10.1038/s41523-022-00386-1
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410917513428992
score 15.198674

Similares en LA Referencia